LJPC

La Jolla Pharmaceutical Company [LJPC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

LJPC Stock Summary

In the News

09:43 29 Mar 2024 LJPC

La Jolla Pharmaceutical Company (LJPC) Stock: Why It Skyrocketed Over 80% Today

The stock price of La Jolla Pharmaceutical Company (NASDAQ: LJPC) surged by over 80% during intraday trading today. This is why.

07:31 29 Mar 2024 LJPC

Moving Average Crossover Alert: La Jolla Pharmaceutical (LJPC)

La Jolla Pharmaceutical (LJPC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

11:16 29 Mar 2024 LJPC

La Jolla Pharmaceutical (LJPC) Misses Q1 Earnings Estimates

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -37.31% and 2.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

08:45 29 Mar 2024 LJPC

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress

WALTHAM, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2021 and highlighted corporate progress. Corporate Progress Operating Cash Flow Improved: La Jolla's net cash provided by (used for) operating activities for the three months ended March

11:22 29 Mar 2024 LJPC

La Jolla Pharmaceutical (LJPC) Reports Q4 Loss, Tops Revenue Estimates

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 62.86% and 7.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

01:41 29 Mar 2024 LJPC

La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

09:47 29 Mar 2024 LJPC

La Jolla Pharma (LJPC) Sees Hammer Chart Pattern: Time to Buy?

La Jolla Pharmaceutical Company (LJPC) has been struggling lately, but the selling pressure may be coming to an end soon.

05:35 29 Mar 2024 LJPC

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2020

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2020. On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. (Tetraphase), a biopharmaceutical company focused on commercializing its novel tetra

12:00 29 Mar 2024 LJPC

Regardless Of Who Wins The White House, This FTSE 100 Stock Could Benefit

Shares Analysis by Investing.com (Tezcan Gecgil/Investing.com) covering: FTSE 100, CRH PLC, Ashtead Group PLC, Vulcan Materials Company. Read Investing.com (Tezcan Gecgil/Investing.com)'s latest article on Investing.com UK.

07:26 29 Mar 2024 LJPC

PNC Financial Services Group Inc. Sells 3,271 Shares of Crh Plc (NYSE:CRH)

PNC Financial Services Group Inc. lessened its stake in Crh Plc (NYSE:CRH) by 26.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,007 shares of the construction company’s stock after selling 3,271 shares during the period. PNC Financial Services Group Inc.’s holdings in CRH […]

LJPC Financial details

Company Rating
Buy
Market Cap
0
Income
1.52M
Revenue
46.49M
Book val./share
-2.17
Cash/share
1.52
Dividend
-
Dividend %
-
Employees
61
Optionable
No
Shortable
Yes
Earnings
15 Aug 2022
P/E
63.77
Forward P/E
-
PEG
-6.19
P/S
-
P/B
-2.26
P/C
-
P/FCF
-
Quick Ratio
3.31
Current Ratio
4.02
Debt / Equity
-0
LT Debt / Equity
-0
-
-
EPS (TTM)
0.04
EPS next Y
-
EPS next Q
-
EPS this Y
-140.28%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
1.13%
EPS Q/Q
76500%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
66.53%
Inst Trans
1.06%
ROA
2%
ROE
-4%
ROC
0.09%
Gross Margin
82%
Oper. Margin
35%
Profit Margin
12%
Payout
-
Shs Outstand
24.94M
Shs Float
11.49M
-
-
-
-
Target Price
-
52W Range
-
52W High
-
52W Low
-
RSI
50
Rel Volume
-
Avg Volume
-
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
2.40789
-
-
Volatility
0.01%, 0.01%
Prev Close
-
Price
-
Change
-

LJPC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.40.851.222.22
Net income per share
-5.41-7.85-4.3-1.440.58
Operating cash flow per share
-4-5.99-3.13-1.380.83
Free cash flow per share
-4.43-6.09-3.16-1.380.83
Cash per share
4.296.793.240.781.37
Book value per share
4.161.41-2.07-3.22-1.95
Tangible book value per share
4.161.41-2.07-4.5-2.93
Share holders equity per share
4.161.41-2.07-3.22-1.95
Interest debt per share
00.291.480.390.38
Market cap
682.7M239.73M106.55M106.04M158.93M
Enterprise value
591.78M67.13M47.98M85.35M114.91M
P/E ratio
-5.95-1.2-0.91-2.698.08
Price to sales ratio
023.844.623.172.1
POCF ratio
-8.04-1.57-1.25-2.825.63
PFCF ratio
-7.26-1.55-1.24-2.825.63
P/B Ratio
7.746.67-1.9-1.2-2.38
PTB ratio
7.746.67-1.9-1.2-2.38
EV to sales
06.682.082.551.52
Enterprise value over EBITDA
-5.21-0.36-0.47-3.383.59
EV to operating cash flow
-6.97-0.44-0.56-2.274.07
EV to free cash flow
-6.29-0.43-0.56-2.274.07
Earnings yield
-0.17-0.83-1.09-0.370.12
Free cash flow yield
-0.14-0.65-0.8-0.350.18
Debt to equity
00-0.52-0.01-0.04
Debt to assets
000.220.010.03
Net debt to EBITDA
0.80.920.580.82-1.37
Current ratio
5.075.953.962.953.82
Interest coverage
0-26.57-10.19-3.572.88
Income quality
0.740.760.730.951.44
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
06.091.651.030.39
Research and developement to revenue
011.663.70.690.07
Intangibles to total assets
0000.480.33
Capex to operating cash flow
0.110.020.0100
Capex to revenue
0-0.23-0.0300
Capex to depreciation
-7.25-0.53-0.1500
Stock based compensation to revenue
03.51.030.190.06
Graham number
22.515.7914.1310.235.03
ROIC
-1.32-5.45-45.380.48-0.47
Return on tangible assets
-0.96-0.98-0.88-1.060.29
Graham Net
2.810.25-3.58-4.82-3.19
Working capital
75.51M150.68M72.87M24.12M49.68M
Tangible asset value
88.2M35.92M-55.99M-123.08M-100.18M
Net current asset value
62.73M12.75M-90.78M-123.87M-100.65M
Invested capital
00-0.52-0.01-0.04
Average receivables
0690.5K2.17M4.4M8.91M
Average payables
9.07M10.03M6.37M3.47M2.52M
Average inventory
01.01M2.12M4.11M6.15M
Days sales outstanding
050.1346.8663.7257.77
Days payables outstanding
01.9K637.38128.9361.64
Days of inventory on hand
0448.75337.38280.69169.96
Receivables turnover
07.287.795.736.32
Payables turnover
00.190.572.835.92
Inventory turnover
00.811.081.32.15
ROE
-1.3-5.552.080.45-0.29
Capex per share
-0.43-0.09-0.0300

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.580.480.440.320.33
Net income per share
0.14-0.080.0500.08
Operating cash flow per share
0.260.030.120.080.21
Free cash flow per share
0.260.030.110.080.21
Cash per share
1.671.71.71.351.52
Book value per share
-2.46-2.49-2.43-2.14-2.17
Tangible book value per share
-3.7-3.72-3.64-3.15-3.18
Share holders equity per share
-2.46-2.49-2.43-2.14-2.17
Interest debt per share
0.20.20.190.080.08
Market cap
117.53M109.71M127.86M140.55M102.34M
Enterprise value
74.38M65.63M83.84M96.66M54.23M
P/E ratio
7.87-12.1424.217.57K10.41
Price to sales ratio
7.328.2410.4713.489.71
POCF ratio
16.47143.2340.4155.7515.32
PFCF ratio
16.47143.2340.5355.7515.32
P/B Ratio
-1.74-1.6-1.92-1.99-1.47
PTB ratio
-1.74-1.6-1.92-1.99-1.47
EV to sales
4.634.936.879.275.14
Enterprise value over EBITDA
10.7967.812.5533.7810.32
EV to operating cash flow
10.4285.6826.538.348.12
EV to free cash flow
10.4285.6826.5738.348.12
Earnings yield
0.03-0.020.0100.02
Free cash flow yield
0.060.010.020.020.07
Debt to equity
-0.04-0.04-0.0400
Debt to assets
0.030.030.0300
Net debt to EBITDA
-6.26-45.54-6.59-15.34-9.16
Current ratio
4.054.123.823.924.02
Interest coverage
1.420.192.5412.04
Income quality
1.91-0.340.841.26K2.72
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.480.530.610.860
Research and developement to revenue
0.070.10.0900.01
Intangibles to total assets
0.340.340.330.340.33
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00-0.0200
Stock based compensation to revenue
0.060.090.10.120.13
Graham number
2.742.141.620.051.93
ROIC
-0.02-0.01-0.03-0.02-0.07
Return on tangible assets
0.06-0.030.0200.04
Graham Net
-4-3.99-3.97-3.4-3.48
Working capital
49.07M49.92M49.68M46.87M49.87M
Tangible asset value
-101.66M-102.24M-100.18M-103.55M-102.14M
Net current asset value
-102.29M-102.79M-100.65M-103.95M-102.47M
Invested capital
-0.04-0.04-0.0400
Average receivables
9.75M12.07M12.08M10.54M7.52M
Average payables
1.47M2.08M2.3M2.53M2.46M
Average inventory
5.43M5.79M6.19M6.7M7.71M
Days sales outstanding
67.0982.2588.3478.650.6
Days payables outstanding
77.0672.5196.25115.67113.1
Days of inventory on hand
228.8190.97265.39295.01441.7
Receivables turnover
1.341.091.021.151.78
Payables turnover
1.171.240.940.780.8
Inventory turnover
0.390.470.340.310.2
ROE
-0.060.03-0.020-0.04
Capex per share
00000

LJPC Frequently Asked Questions

What is La Jolla Pharmaceutical Company stock symbol ?

La Jolla Pharmaceutical Company is a US stock , located in San diego of California and trading under the symbol LJPC

What is La Jolla Pharmaceutical Company stock quote today ?

La Jolla Pharmaceutical Company stock price is $- today.

Is La Jolla Pharmaceutical Company stock public?

Yes, La Jolla Pharmaceutical Company is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Check Those
Similar Market Cap